SRR12475118
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- UV_RESPONSE_DN+0.360
- MYOGENESIS+0.350
- ANGIOGENESIS+0.340
- HEDGEHOG_SIGNALING+0.200
- COAGULATION+0.170
- APICAL_JUNCTION+0.160
- KRAS_SIGNALING_UP+0.140
- PANCREAS_BETA_CELLS+0.140
- APICAL_SURFACE+0.130
Top 10 suppressed
- MYC_TARGETS_V2-0.550
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.470
- P53_PATHWAY-0.340
- GLYCOLYSIS-0.320
- MTORC1_SIGNALING-0.320
- MYC_TARGETS_V1-0.310
- DNA_REPAIR-0.270
- NOTCH_SIGNALING-0.270
- INTERFERON_ALPHA_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6b32f047-89ca-40e7-950f-a03493ea90c7 | — | — | 0.890 |
| 2 | MBCProject_1493_T1_RNA | — | A | 0.871 |
| 3 | SRR8613742 | — | A | 0.869 |
| 4 | SRR26320068 | — | — | 0.861 |
| 5 | SRR8518451 | — | A | 0.858 |
| 6 | 8aaaa253-87d2-4292-aeb2-1b207b71abef | — | — | 0.857 |
| 7 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.857 |
| 8 | SRR15069598 | — | — | 0.847 |
| 9 | DRR168582 | — | — | 0.845 |
| 10 | a545f8c1-39e3-48cc-8c22-897c5d3a21ea | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |